胆管癌：分类负担日益加重。
Cholangiocarcinoma: increasing burden of classifications.
作者信息
Cardinale Vincenzo, Bragazzi Maria Consiglia, Carpino Guido, Torrice Alessia, Fraveto Alice, Gentile Raffaele, Pasqualino Vincenzo, Melandro Fabio, Aliberti Camilla, Bastianelli Carlo, Brunelli Roberto, Berloco Pasquale Bartolomeo, Gaudio Eugenio, Alvaro Domenico
机构信息
Department of Medico-Surgical Sciences and Biotechnologies, Polo Pontino, Rome, Italy;
Department of Anatomical, Histological, Forensic Medicine and Orthopedics Sciences, Rome, Italy; ; Department of Movement, Human and Health Sciences, Division of Health Sciences, University of Rome "Foro Italico", Rome, Italy;
出版信息
Hepatobiliary Surg Nutr. 2013 Oct;2(5):272-80. doi: 10.3978/j.issn.2304-3881.2013.10.02.
Abstract
Cholangiocarcinoma (CCA) is a very heterogeneous cancer from any point of view, including epidemiology, risk factors, morphology, pathology, molecular pathology, modalities of growth and clinical features. Given this heterogeneity, a uniform classification respecting the epidemiologic, pathologic and clinical needs is currently lacking. In this manuscript we discussed the different proposed classifications of CCA in relation with recent advances in pathophysiology and biology of this cancer.
摘要
胆管癌（CCA）从任何角度来看都是一种高度异质性的癌症，包括流行病学、危险因素、形态学、病理学、分子病理学、生长方式及临床特征等方面。鉴于这种异质性，目前缺乏一种符合流行病学、病理学及临床需求的统一分类方法。在本手稿中，我们结合该癌症病理生理学和生物学的最新进展，讨论了CCA不同的分类方法。
相似文献
1
Cholangiocarcinoma: increasing burden of classifications.胆管癌：分类负担日益加重。
Hepatobiliary Surg Nutr. 2013 Oct;2(5):272-80. doi: 10.3978/j.issn.2304-3881.2013.10.02.
2
Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors.肝内和肝外胆管癌：流行病学和危险因素的新见解。
World J Gastrointest Oncol. 2010 Nov 15;2(11):407-16. doi: 10.4251/wjgo.v2.i11.407.
3
Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.胆管癌的多细胞起源是其生物学、流行病学和临床异质性的基础。
World J Gastrointest Oncol. 2012 May 15;4(5):94-102. doi: 10.4251/wjgo.v4.i5.94.
4
New insights into cholangiocarcinoma: multiple stems and related cell lineages of origin.胆管癌的新见解：多个起源干细胞及相关细胞谱系
Ann Gastroenterol. 2018 Jan-Feb;31(1):42-55. doi: 10.20524/aog.2017.0209. Epub 2017 Nov 2.
5
Pathologic classification of cholangiocarcinoma: New concepts.胆管癌的病理分类：新概念
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):277-93. doi: 10.1016/j.bpg.2015.02.006. Epub 2015 Feb 17.
6
Molecular classification of cholangiocarcinoma.胆管癌的分子分类。
Curr Opin Gastroenterol. 2020 Mar;36(2):57-62. doi: 10.1097/MOG.0000000000000611.
7
Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.混合型肝细胞胆管细胞癌肿瘤：胆管细胞癌是一种独特的分子实体。
J Hepatol. 2017 May;66(5):952-961. doi: 10.1016/j.jhep.2017.01.010. Epub 2017 Jan 23.
8
Selecting an Appropriate Experimental Animal Model for Cholangiocarcinoma Research.为胆管癌研究选择合适的实验动物模型。
J Clin Transl Hepatol. 2022 Aug 28;10(4):700-710. doi: 10.14218/JCTH.2021.00374. Epub 2022 Feb 11.
9
Cell of origin in biliary tract cancers and clinical implications.胆管癌的起源细胞及其临床意义。
JHEP Rep. 2021 Jan 19;3(2):100226. doi: 10.1016/j.jhepr.2021.100226. eCollection 2021 Apr.
10
Morphomolecular Pathology and Genomic Insights into the Cells of Origin of Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma.胆管癌和肝细胞胆管癌起源细胞的形态分子病理学与基因组学见解
Am J Pathol. 2025 Mar;195(3):345-361. doi: 10.1016/j.ajpath.2024.08.014. Epub 2024 Sep 26.
引用本文的文献
1
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study.瑞戈非尼联合改良吉西他滨-奥沙利铂治疗晚期胆管癌。随机Ib/II期BREGO研究。
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf080.
2
Identification of Novel Protein Biomarkers for Intrahepatic Cholangiocarcinoma by Integrating Human Plasma Proteome with Genome.通过整合人类血浆蛋白质组与基因组鉴定肝内胆管癌的新型蛋白质生物标志物
J Gastrointest Cancer. 2025 Apr 17;56(1):100. doi: 10.1007/s12029-025-01226-8.
3
Multi-Omics Classification of Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis.肝内胆管癌的多组学分类：系统评价与Meta分析
Cancers (Basel). 2024 Jul 20;16(14):2596. doi: 10.3390/cancers16142596.
4
New Insights in the Setting of Transplant Oncology.移植肿瘤学领域的新见解。
Medicina (Kaunas). 2023 Mar 14;59(3):568. doi: 10.3390/medicina59030568.
5
Characteristic Analysis of Featured Genes Associated with Cholangiocarcinoma Progression.与胆管癌进展相关的特征基因的特征分析
Biomedicines. 2023 Mar 10;11(3):847. doi: 10.3390/biomedicines11030847.
6
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective.优化胆道晚期癌症患者的治疗路径：最新进展和法国视角。
Target Oncol. 2023 Jan;18(1):51-76. doi: 10.1007/s11523-022-00942-6. Epub 2023 Feb 6.
7
Identification and Validation of Novel Biomarkers and Potential Targeted Drugs in Cholangiocarcinoma: Bioinformatics, Virtual Screening, and Biological Evaluation.胆管癌新型生物标志物的鉴定和验证：生物信息学、虚拟筛选和生物学评价。
J Microbiol Biotechnol. 2022 Oct 28;32(10):1262-1274. doi: 10.4014/jmb.2207.07037. Epub 2022 Sep 13.
8
Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells.金雀异黄素使人类胆管癌细胞系对自然杀伤细胞敏感。
Biology (Basel). 2022 Jul 23;11(8):1098. doi: 10.3390/biology11081098.
9
Comparison of growth features and cancer stem cell prevalence in intrahepatic and extrahepatic cholangiocarcinoma cell lines.肝内和肝外胆管癌细胞系生长特征及癌症干细胞患病率的比较
Clin Exp Hepatol. 2022 Mar;8(1):60-69. doi: 10.5114/ceh.2022.114192. Epub 2022 Mar 23.
10
Alternative Splicing-Based Differences Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: Genes, Immune Microenvironment, and Survival Prognosis.基于可变剪接的肝细胞癌与肝内胆管癌之间的差异：基因、免疫微环境和生存预后
Front Oncol. 2021 Oct 25;11:731993. doi: 10.3389/fonc.2021.731993. eCollection 2021.
本文引用的文献
1
Isolation and characterization of biliary epithelial and stromal cells from resected human cholangiocarcinoma: a novel in vitro model to study tumor-stroma interactions.从切除的人胆管癌中分离和鉴定胆管上皮和基质细胞：研究肿瘤-基质相互作用的新型体外模型。
Oncol Rep. 2013 Sep;30(3):1143-8. doi: 10.3892/or.2013.2568. Epub 2013 Jun 26.
2
Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update.胆管癌诊断和治疗指南：更新版。
Gut. 2012 Dec;61(12):1657-69. doi: 10.1136/gutjnl-2011-301748. Epub 2012 Aug 15.
3
Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity.胆管癌的多细胞起源是其生物学、流行病学和临床异质性的基础。
World J Gastrointest Oncol. 2012 May 15;4(5):94-102. doi: 10.4251/wjgo.v4.i5.94.
4
Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?胆管内乳头状肿瘤：胆管内乳头状黏液性肿瘤相当于胰腺内的肿瘤吗？
Hepatology. 2012 Oct;56(4):1352-60. doi: 10.1002/hep.25786. Epub 2012 Aug 27.
5
Cholangiocarcinoma: a cancer in search of the right classification.胆管癌：一种寻求正确分类的癌症。
Hepatology. 2012 Oct;56(4):1585-6; author reply 1586. doi: 10.1002/hep.25705.
6
Cystic and papillary neoplasm involving peribiliary glands: a biliary counterpart of branch-type intraductal papillary mucinous [corrected] neoplasm?累及胆管周围腺体的囊性和乳头状肿瘤：分支型导管内乳头状黏液性肿瘤的胆管对应物？[已修正]
Hepatology. 2012 Jun;55(6):2040-1. doi: 10.1002/hep.25590.
7
Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages.肝外和肝内胆管腺体中的胆管树干/祖细胞：一项提供成熟谱系证据的解剖原位研究。
J Anat. 2012 Feb;220(2):186-99. doi: 10.1111/j.1469-7580.2011.01462.x. Epub 2011 Dec 5.
8
Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets.人胆管中的多能干细胞/祖细胞可分化为肝细胞、胆管细胞和胰岛细胞。
Hepatology. 2011 Dec;54(6):2159-72. doi: 10.1002/hep.24590.
9
Clinical diagnosis and staging of cholangiocarcinoma.胆管癌的临床诊断和分期。
Nat Rev Gastroenterol Hepatol. 2011 Aug 2;8(9):512-22. doi: 10.1038/nrgastro.2011.131.
10
Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization.核表达 S100A4 钙结合蛋白增加胆管癌的侵袭和转移。
Hepatology. 2011 Sep 2;54(3):890-9. doi: 10.1002/hep.24466.
Zotero 插件